Zentalis Pharmaceuticals, Inc.ZNTLNASDAQ
Loading
Operating Income Growth Under PressureDecelerating
Percentile Rank73
3Y CAGR-23.9%
Year-over-Year Change
Year-over-year operating income growth rate
3Y CAGR
-23.9%/yr
Quarterly compound
Percentile
P73
Within normal range
vs 3Y Ago
0.4x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q3 2025 | 6.45% |
| Q2 2025 | 20.97% |
| Q1 2025 | 8.48% |
| Q4 2024 | 3.08% |
| Q3 2024 | 21.05% |
| Q2 2024 | -163.06% |
| Q1 2024 | 63.54% |
| Q4 2023 | -8.30% |
| Q3 2023 | 39.65% |
| Q2 2023 | -59.99% |
| Q1 2023 | -25.50% |
| Q4 2022 | 4.50% |
| Q3 2022 | 14.60% |
| Q2 2022 | -9.64% |
| Q1 2022 | -20.10% |
| Q4 2021 | 23.34% |
| Q3 2021 | -14.04% |
| Q2 2021 | -9.50% |
| Q1 2021 | -25.10% |
| Q4 2020 | -15.76% |
| Q3 2020 | -27.00% |
| Q2 2020 | -66.94% |
| Q1 2020 | -10.02% |
| Q4 2019 | -18.45% |
| Q3 2019 | -18.32% |
| Q2 2019 | -21.93% |
| Q1 2019 | 0.00% |